Expression III研究:1830例欧洲卵巢癌患者对医患关系及临床管理的期望与偏好
该国际NOGGO/ENGOT-ov4-GCIG研究通过问卷调查了8个欧洲国家1830例卵巢癌患者(初诊902例,复发731例),了解其对信息需求和治疗偏好。患者对诊断和治疗方案解释的完整性与可理解性多数满意;改善治疗最重要的三个方面为治疗不引起脱发(42%)、更多应对疲劳(34.5%)和治疗更有效(29.7%)。
要点
- 患者对治疗选择相关信息需求高,不受文化背景、疾病阶段和年龄影响。
- 脱发(42%)、疲劳(34.5%)和治疗更有效(29.7%)是患者最关注的改善方面。
- 659例(36%)被提供临床试验参与机会,其中476例(26%)被纳入。
核心结论
- 卵巢癌患者对治疗选择所有细节信息需求高,且对潜在副作用和治疗替代方案的信息需求增加。
- 除需要更有效治疗外,脱发和疲劳是患者最关注的不良反应。
研究设计与样本
- 基于德国Expression II调查经验开发问卷,通过互联网(在线版)或打印版提供给初诊或复发卵巢癌患者。
- 初诊后902例(49.3%),复发卵巢癌731例(39.9%);中位年龄58岁(范围17-89)。
主要发现
- 几乎所有患者(96.2%)接受过初始手术,随后一线化疗(91.8%)。
- 多数患者对诊断和治疗方案解释的完整性和可理解性满意。
- 患者认为改善卵巢癌治疗最重要的三个方面:治疗不引起脱发(42%)、更多应对疲劳(34.5%)、治疗更有效(29.7%)。
- 659例(36%)被提供临床试验参与机会,其中476例(26%)被纳入。
临床怎么用
- 临床沟通中应充分提供治疗选择细节,并主动讨论脱发和疲劳等不良反应的管理。
- 应关注患者对潜在副作用和治疗替代方案的信息需求,不受年龄、疾病阶段和文化背景影响。
局限性
- 问卷通过互联网或打印版发放,可能存在选择偏倚。
- 研究未报告问卷回收率或应答率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKROUND: The primary aim of this study was to investigate information needs and treatment preferences of patients with ovarian cancer, focusing especially on physician-patient relationship and treatment. PATIENTS AND METHODS: A questionnaire was developed based on the experiences of the national German survey 'Expression II', and was provided to patients with ovarian cancer either at initial diagnosis or with recurrent disease via Internet (online-version) or as print-out-version. RESULTS: From December 2009 to October 2012, a total of 1830 patients with ovarian cancer from eight European countries (Austria, Belgium, France, Germany, Italy, Poland, Romania, Spain) participated, 902 (49.3%) after initial diagnosis and 731 (39.9%) with recurrent ovarian cancer. The median age was 58 years (range 17-89). Nearly all patients (96.2%) had experienced upfront surgery followed by first-line chemotherapy (91.8%). The majority of patients were satisfied with the completeness and comprehensibility of the explanation about the diagnosis and treatment options. The three most important aspects, identified by patients to improve the treatment for ovarian cancer included: 'the therapy should not induce alopecia' (42%), 'there must be more done to counter fatigue' (34.5%) and 'the therapy should be more effective' (29.7%). Out of 659 (36%) patients, who were offered participation in a clinical trial, 476 (26%) were included. CONCLUSION: This study underlines the high need of patients with ovarian cancer for all details concerning treatment options irrespective of their cultural background, the stage of disease and the patient's age. Increased information requirements regarding potential side effects and treatment alternatives were recorded. Besides the need for more effective therapy, alopecia and fatigue are the most important side effects of concern to patients.
引用
- Oskay-Özcelik G, Alavi S, Richter R, et al. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol. 2018. PMID: 29415128. doi:10.1093/annonc/mdy037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。